While SGLT2 inhibitors have modest effects on weight and glycemia, GLP-1RAs have shown more pronounced effects on both weight and glycemia, particularly in those with obesity or suboptimal glycemic control, highlighting their potential as a comprehensive treatment option in DKD [26]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.